|
|
 | | | |
- close
- close
- close
- close
Valeant Pharmaceuticals International (VRX) |
FiercePharma
Jun 10
Comment
Despite the growth potential in Galenika's home country of Serbia, Valeant was the only suitor so far willing to enter a market rife with corruption. Now, it has backed out of its offer to buy the ailing state-run drugmaker amid agitation in...
Market Intelligence Center
Jun 10
Comment
Valeant Pharmac. (NYSE: VRX) closed Friday's trading session at $85.59. In the past year, the stock has hit a 52-week low of $42.47 and 52-week high of $96.25. Valeant Pharmac. (VRX) stock has been showing support around $84.00 and resistance in...
StreetInsider.com
Jun 10
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/CRT+Capital+Upgrades+Valeant+Pharmaceuticals+%28VRX%29+to+Buy/8401645.html for the full story.
Benzinga
Jun 7
Comment
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it has filed a preliminary base shelf prospectus in Canada. The preliminary base shelf prospectus was filed with securities regulatory authorities in each of...
Reuters
Jun 7
Comment
Canada's Valeant has pulled out of a possible bid for a Serbian drug company in the wake of its $8.7 billion purchase of contact lenses maker Bausch & Lomb.
The Globe and Mail
Jun 5
Comment
Plus: Canaccord figures Valeant could save $800-million in costs after Bausch & Lomb deal
Market Intelligence Center
Jun 4
Comment
Valeant Pharmac. (NYSE: VRX) closed Monday's trading session at $88.21. In the past year, the stock has hit a 52-week low of $42.47 and 52-week high of $96.25. Valeant Pharmac. (VRX) stock has been showing support around $85.79 and resistance in...
Benzinga
Jun 3
Comment
Hyperion
Therapeutics, Inc. (Nasdaq: HPTX) today announced the completion of its
acquisition of BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, an
FDA-approved therapy for treatment of the most prevalent urea cycle disorders
(UCD), from...
StreetInsider.com
May 31
Comment
1. Last Monday, Valeant Pharmaceuticals (NYSE: VRX) confirmed a deal to acquire privately-equity owned Bausch + Lomb Holdings Incorporated for $8.7 billion in cash. Rumors of the deal hit markets on Friday, driving shares of Valeant 13% higher....
FiercePharma
May 31
Comment
There's no shame in a company extending a bidding deadline in hopes of attaining a better offer. But after extending its deadline for the fourth time Thursday to June 14, Serbia's state-run drugmaker Galenika Pharmaceuticals may be starting to...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
